Who is sponsoring NCT03237819?

NCT03237819 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT03237819?

Interventions in NCT03237819: Sulfate, Magnesium, Placebo - Concentrate.

What condition does NCT03237819 study?

NCT03237819 studies Thrombotic Thrombocytopenic Purpura.

Is NCT03237819 still recruiting?

NCT03237819 is currently status unknown. Last updated 29 October 2021.

Last reviewed 2021-10-29 · How we verify

NCT03237819: MAGMAT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care

Status unknown Phase 3 Last updated 29 October 2021

What this trial tests

Phase 3 trial testing Sulfate, Magnesium in Thrombotic Thrombocytopenic Purpura in 74 participants. Status unknown.

Timeline

27 May 2018

Primary endpoint
1 December 2021

1 December 2021

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	74
Start date	27 May 2018
Primary completion	1 December 2021
Estimated completion	1 December 2021
Sites	1 location across France

Drugs / interventions tested

Sulfate, Magnesium — full drug profile →
Placebo - Concentrate — full drug profile →

Conditions studied

Thrombotic Thrombocytopenic Purpura — all drugs for Thrombotic Thrombocytopenic Purpura →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Thrombotic Thrombocytopenic Purpura. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Thrombotic Thrombocytopenic Purpura (TTP) is a potentially life-threatening thrombotic microangiopathy caused by a severe deficiency of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13). Decreased ADAMTS13 activity leads to an accumulation of ultralarge von Willebrand factor (vWF) multimers which induce aggregation of platelets and microthrombi. These microthrombi may involve the brain, heart, kidneys and lead to life-threatening organ failures. In experimental models, magnesium sulfate increases cleavage of newly released vWF by ADAMTS13, decreases the endothelial secretion of ultralarge vWF and inhibits the interaction of vWF with platelets. In another thrombotic microangiopathy, magnesium sulfate has been shown to reduce the risk of seizures in women with severe pre-eclampsia. In analogy with its evidence-based therapeutic application in pre-eclampsia and based on a strong rationale for magnesium supplementation in TTP, we propose a phase 3, double blind, placebo controlled, and randomized study to evaluate the efficacy of magnesium sulfate in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis in patients with Thrombotic Thrombocytopenic Purpura.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Thrombotic Thrombocytopenic Purpura

Currently open trials in the same condition.

NCT06727669 — Longitudinal Cohort of Thrombosis and Hemostasis Diseases · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03237819 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 29 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03237819.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing